Compare EMBC & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EMBC | KMDA |
|---|---|---|
| Founded | 1924 | 1990 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 521.7M | 501.8M |
| IPO Year | 2021 | 2013 |
| Metric | EMBC | KMDA |
|---|---|---|
| Price | $8.84 | $8.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $18.50 | $14.00 |
| AVG Volume (30 Days) | ★ 766.6K | 71.6K |
| Earning Date | 05-08-2026 | 03-11-2026 |
| Dividend Yield | ★ 6.67% | 3.05% |
| EPS Growth | ★ 20.90 | N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.17 | $13.94 |
| Revenue Next Year | N/A | $9.84 |
| P/E Ratio | ★ $12.16 | $24.59 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.72 | $5.54 |
| 52 Week High | $15.55 | $9.35 |
| Indicator | EMBC | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 36.01 | 39.49 |
| Support Level | $8.72 | $6.62 |
| Resistance Level | $9.47 | $8.30 |
| Average True Range (ATR) | 0.35 | 0.24 |
| MACD | 0.05 | -0.10 |
| Stochastic Oscillator | 15.35 | 10.78 |
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.